• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

MiniMed claims quick FDA clearance for Fit patch pump

November 16, 2026 By Conor Hale

The waterproof MiniMed Fit
The waterproof MiniMed Fit sports a wear time of 7 days. [Image courtesy of MiniMed]
After submitting its patch pump for FDA review in late August, MiniMed (Nasdaq: MMED) has turned around a quick clearance for the Fit automated insulin delivery system.

The Fit marks the company’s first tubeless design, carrying a 300-unit insulin capacity and a seven-day wear time that does not require recharging or cartridge changes.

For continuous glucose monitor compatibility, the waterproof wearable is set to launch next year with links to MiniMed’s seven-day Simplera Sync as well as the 15-day Instinct sensor made for the company by Abbott. The patch pump will also be controlled by iOS and Android smartphone apps.

“Clearing FDA ahead of schedule is more proof we’re executing our strategy,” MiniMed CEO Que Dallara said in a statement. “It puts MiniMed Fit in U.S. customers’ hands sooner, and the pharmacy channel makes it easier to get.”

Related: MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

The company is now planning a phased U.S. commercial rollout for spring 2027. Previously it had aimed for an autumn submission to the FDA, followed by a summer 2027 release.

Last week the agency also handed a clearance to a tubeless version of Tandem Diabetes Care’s Mobi pump, with a cartridge and infusion set that can be worn on the skin for up to a week. That 200-unit system, which requires an insulin cartridge change after three days, is scheduled for a U.S. launch in the first half of next year.

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA) Tagged With: minimed

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS